Domaine de Maîtrise :
Recherche Clinique

Domaine d’intérêt :
Recherche Clinique, Nouvelles Technologies - Ingénierie - Systèmes d’Information et IA

Les publications :
1.Lakhlili W, Chevé G, Yasri A, Ibrahimi A. Determination and validation of mTOR kinase-domain 3D structure by homology modeling.Onco Targets Ther. 2015 Jul 30;8:1923-30. doi: 10.2147/OTT.S84200. eCollection 2015. PMID: 26257525 2.Lakhlili W, Yasri A, Ibrahimi A.Structure-activity relationships study of mTOR kinase inhibition using QSAR and structure-based drug design approaches. Onco Targets Ther. 2016 Dec 2;9:7345-7353. eCollection 2016. PMID: 27980424 3.Allam L, Lakhlili W, Tarhda Z, Akachar J, Ghrifi F, El Amri H and Ibrahimi A. Three-dimensional Structure Prediction of the Human LMTK3 Catalytic Domain in DYG-in Conformation. J Biomol Res Ther. 2017; 6:151 4.Kandoussi I, Lakhlili W, Taoufik J, Ibrahimi A. Docking analysis of verteporfin with YAP WW domain. Bioinformation. 2017 Jul 31;13(7):237-240. eCollection 2017.PMID: 28943729 5.Ghrifi F, Allam L, Lakhlili W and Ibrahimi A In Silico Inhibition Studies of AXL Kinase by Curcumin and its Natural Derivatives. J ApplBioinformaComputBiol 2017 6:3doi: 10.4172/2329-9533.1000142 6.Allam L, Ghrifi F, Lakhlili W, El Amri H and Ibrahimi A. Molecular screening and docking analysis of LMTK3 and AKT1 combined inhibitors Bioinformation 2018 14(9) 499-503. 7.Arrouchi H, Lakhlili W, Ibrahimi A. A review on PIM kinases in tumors Bioinformation 2019 15(1): 40-45 8.Arrouchi H, Lakhlili W, Ibrahimi A. Re-positioning of known drugs for Pim-1 kinase target using molecular docking analysis Bioinformation 2019 15(2): 118-120 9.Ghrifi F, Allam L, Lakhlili W and Ibrahimi A. Curcumin-synthetic analogs Library Screening by Docking and QSAR studies for AXL tyrosine kinase inhibition in cancers. Journal of Computational Biology 2019 Published Online: 24 Jun 2019 https://doi.org/10.1089/cmb.2019.0052